Feb 3, 2020:Accumen Inc. announced that its 3DR Labs, LLC company is partnering with Resonance Health Limited in order to provide FerriSmart magnetic resonance imaging- (MRI-) based liver iron concentration reports for its clients.
FerriSmart uses artificial intelligence (AI) in order to analyze MRI images and deliver a liver iron quantification result within seconds.
This technology allows liver iron concentrations to be monitored efficiently and powerfully for individuals with confirmed or suspected systemic iron overload, patients with thalassemia or sickle cell anaemia who require regular blood transfusions, and recipients of artificial heart valves who may experience an increase in systemic iron levels over time.
Sickle cell disease is the group of inherited red blood cell disorders, characterized by hard, sticky, c-shaped red blood cells. These RBC’s die early, so they are always in short supply.
They also lean to cause blood clots, which can result in pain, infection, acute chest syndrome and stroke. The US Centers for the Disease Control and Prevention estimates that sickle cell disease affects about 100,000 Americans and millions of people throughout the world.
Thalassemia is a group of inherited disorders in which there is reduced haemoglobin levels, decreased red blood cell production and anaemia.
They are sub-divided into alpha-thalassemia and beta-thalassemia depending on whether the mutation occurs on the alpha or beta chain of haemoglobin molecule.
Resonance Health has received 510(k) clearance for the FerriSmart from the US FDA, a CE mark from the European Medicines Agency, and regulatory clearance from the Therapeutic Goods Administration in Australia.
https://accumen.com/accumens-3dr-labs-partners-with-resonance-health-to-expand-its-mri-analysis-services/
